Page last updated: 2024-11-13
sch 37224
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Sch 37224: structure in first source; inhibits leukotriene formation; inhibits thromboxane B2 release [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54680204 |
| CHEMBL ID | 2105217 |
| SCHEMBL ID | 125349 |
| SCHEMBL ID | 125348 |
| MeSH ID | M0162157 |
Synonyms (23)
| Synonym |
|---|
| sch-37224 |
| pirodomast |
| 2-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-4-one |
| ULGABHCZIJXUFO-UHFFFAOYSA-N |
| CHEMBL2105217 |
| unii-1s2eov9v3z |
| pirodomastum |
| 108310-20-9 |
| sch 37224 |
| pirodomast [inn] |
| 1s2eov9v3z , |
| pirodomastum [inn-latin] |
| 1-(1,2-dihydro-4-hydroxy-2-oxo-1-phenyl-1,8-naphthyridin-3-yl)pyrrolidinium |
| 1,8-naphthyridin-2(1h)-one, 4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)- |
| 4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1h)-one |
| 4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2-(1h)-one |
| SCHEMBL125349 |
| SCHEMBL125348 |
| DTXSID20148498 |
| sch37224 |
| Q27252828 |
| 4-hydroxy-1-phenyl-3-pyrrolidin-1-yl-1,8-naphthyridin-2-one |
| methyl3,6-dichloro-1-benzothiophene-2-carboxylate |
Research Excerpts
Overview
Sch 37224 is an experimental antiallergy compound. It inhibits hyperventilation-induced bronchoconstriction (HIB) in guinea pigs and cold air bronchospasm in human asthmatics.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sch 37224 is an experimental antiallergy compound that inhibits hyperventilation-induced bronchoconstriction (HIB) in guinea pigs and cold air bronchospasm in human asthmatics. " | ( Sch 37224, an experimental antiallergy compound, inhibits the neuropeptide component of hyperventilation- and nicotine-induced bronchoconstriction in guinea pigs. Anthes, J; Chapman, RW; Egan, RW; Greenfeder, S; Hey, JA; Kreutner, W; Mauser, PJ; Rasquinha, C; Sherwood, JE, 1997) | 3.18 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Sch 37224 treatment reduced the peak immediate and peak late increases in SRL to 128 +/- 32 and 43 +/- 17%, respectively (both P less than .05 vs." | ( A leukotriene and thromboxane inhibitor (Sch 37224) blocks antigen-induced immediate and late responses and airway hyperresponsiveness in allergic sheep. Abraham, WM; Garrido, R; Stevenson, JS, 1988) | 1.26 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " For these studies, base-line airway dose-response curves to histamine and carbachol were determined on the same day." | ( A leukotriene and thromboxane inhibitor (Sch 37224) blocks antigen-induced immediate and late responses and airway hyperresponsiveness in allergic sheep. Abraham, WM; Garrido, R; Stevenson, JS, 1988) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||